



OK TO  
ENTER  
EX CUSA  
4/15/03

**F A X C O V E R**

\*\*\*\*\*OFFICIAL FAX\*\*\*\*\*

**Date:** April 14, 2003 **Number of pages (including cover):** 7  
**To:** Examiner B. Celsa, U.S. Patent and Trademark Office  
**Fax No.:** 703-746-5007  
**Serial No.:** 09/706,574  
**Title:** METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY...  
**From:** John R. Van Amsterdam, Ph.D.  
**Direct dial:** 617.573.7833  
**Our File #:** M006556.70060.US

**CERTIFICATE OF FACSIMILE TRANSMISSION 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being transmitted via facsimile to the attention of Examiner Examiner B. Celsa, FAX number 703-746-5007, at the United States Patent and Trademark Office, Washington, D.C. 20231, in accordance with 37 C.F.R. §1.6(d), on the 14th day of April, 2003.

  
John R. Van Amsterdam, Ph.D.

**ORIGINAL DOCUMENTS WILL NOT BE MAILED.**

**MESSAGE:** Transmitted herewith is/are Copies of: (1) Supplemental response to species requirement, (2) Structure of CNQX, (3) Petition for one month extension of time, (4) Transmittal dated Nov. 12, 2002. (5) Postcard mailed Nov. 12, 2002 and stamped as received by PTO Nov. 19, 2002.

This transmission contains confidential information intended for use only by the above-named recipient. Reading, discussing, distributing, or copying this message by anyone other than the named recipient, or his or her employees or agents, is strictly prohibited. If you have received this fax in error, please notify us immediately by telephone (collect), and return the original message to us at the address below via the U.S. Postal Service.

**IF YOU DID NOT RECEIVE ALL OF THE PAGES OF THIS TRANSMISSION, OR IF ANY OF THE PAGES ARE ILLEGIBLE, PLEASE CALL 617.720.3500 IMMEDIATELY.**

**Wolf Greenfield Fax Number: 617.720.2441**

Wolf, Greenfield & Sacks, P.C. | 600 Atlantic Avenue | Boston, Massachusetts 02210-2206  
617.720.3500 | fax 617.720.2441 | [www.wolfgreenfield.com](http://www.wolfgreenfield.com)

**PATENTS TRADEMARKS COPYRIGHTS TECHNOLOGY TRANSFERS LITIGATION**

Attorney's Docket No: M00656.70060.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Ingram and Blanchard  
Serial No. : 09/706,574  
Filed : November 3, 2000  
For : METHODS FOR IDENTIFYING TREATMENTS FOR  
NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED  
BY  $\beta$ -AMYLOID PEPTIDES  
Examiner : B. Celsa  
Art Unit : 1627

#16  
Guar  
4/10-03

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 12th day of November, 2002.

  
John R. Van Amsterdam

Commissioner for Patents  
Washington, D.C. 20231

Sir:

SUPPLEMENTAL RESPONSE TO SPECIES REQUIREMENT

In response to the restriction requirement mailed April 11, 2002, Applicants previously elected Group IV claims (40-49), and as a species, small organic molecules, with traverse as to the species restriction. Applicants maintain that traversal.


In the Communication mailed September 9, 2002, the Examiner reiterated that Applicants were to make an election of a specific small molecule disclosed in the specification or claims. In response, Applicants elect CNQX. The structure of this molecule is appended hereto as requested. Applicants believe that claims 40, 42-45, and 47-49 are readable on the elected compound, CNQX.

Applicants traverse the requirement for the election of a specific small organic molecule, because the elected method claims recite methods for screening candidate pharmacological agents based on the recognition that A $\beta$  aggregates induce changes in the depolarization state of cells that can be measured using cells loaded with potentiometric compounds. By their very nature as candidate agents, the class of small molecules elected for prosecution should not be

658189.1

limited to any particular molecule. Moreover, many small molecules that might be identified with the claimed methods were not recited in the application. Accordingly, Applicants object to the requirement that a specific molecule be selected, and respectfully request reconsideration of the requirement.

Respectfully submitted,

  
\_\_\_\_\_  
John R. Van Amsterdam, Reg. No. 40,212  
WOLF, GREENFIELD & SACKS, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210  
Tel: (617) 720-3500

Attorney's Docket No. M00656.70060.US  
Dated: November 12, 2002  
X11/09/02


528131.1

Attorney's Docket No: M00656.70060.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Ingram and Blanchard  
Serial No. : 09/706,574  
Filed : November 3, 2000  
For : METHODS FOR IDENTIFYING TREATMENTS FOR  
NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED  
BY  $\beta$ -AMYLOID PEPTIDES  
Examiner : B. Celsa  
Art Unit : 1627

STRUCTURE OF CNOX



658185.1